ReviewPharmacoEconomics - open2021

Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Rachel Houten et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.